IFNA17 and hypothyroidism: In a more recent study, Wahid et al. [30] confirmed a high risk of hypothyroidism in two groups of HCV patients treated with different DAAs drugs regimens (sofosbuvir + IFN-α + ribavirin and sofosbuvir + daclatasvir + ribavirin), with higher prevalence of hypothyroidism in the first DAAs group.